Results 31 to 40 of about 46,198 (239)
Tissue specific accumulation of hydroxyurea in elasmobranchs [PDF]
Hydroxyurea is an antibiotic and antiproliferative agent used clinically in the treatment of select cancers, sickle cell anemia, HIV, and myeloproliferative diseases.
Fraser, David Iain
core +1 more source
Hydroxyurea therapy lowers circulating DNA levels in sickle cell anemia
Hydroxyurea reduces the frequency of acute pain in sickle cell disease (SCD). We sought to determine if hydroxyurea therapy affects cell free DNA (cfDNA) levels in SCD. cfDNA levels fell in all 10 patients studied; before hydroxyurea, mean was 1,879 (95%
Rees, D C +8 more
core +1 more source
Chromatographic conditions for the quantification of hydroxyurea.
Chromatographic conditions for the quantification of hydroxyurea.
Annie Viau (12936671) +7 more
core +1 more source
In several systems, hydroxyurea has been shown to trigger nitric oxide (NO) release or activation of NO synthase (NOS). To elucidate this duality in its pharmacological effects, during myelosuppression, we individually examined hydroxyurea’s (NO ...
Tijana Subotički +6 more
doaj +1 more source
Pneumopathie induite par l'hydroxyurée. [Hydroxyurea-induced pneumonia].
International audienceIntroduction: Hydroxyurea is an antimetabolite widely used in the treatment of myeloproliferative diseases. Usual side effects are mainly hematological, gastrointestinal, neurological disorders and induced-fevers.
Poullot, Elsa +7 more
core +1 more source
ABSTRACT The medical burdens of sickle cell disease (SCD) and transfusion‐dependent β‐thalassemia (TDT) are chronic and cumulative, even in children. Yet the effects expand beyond medications and healthcare visits due to their impacts on school attendance, academic performance, and peer engagement.
Mary Ann Etling +2 more
wiley +1 more source
Hydroxyurea is an antineoplastic agent used alone or in combination with other chemotherapeutic drugs or radiation in the treatment of resistant leukemias and carcinomas of the head and neck.
Khandhar, Paras B, Jinna, Sruthi
core
Background/Objectives: Hydroxyurea is currently the standard disease-modifying therapy for reducing sickle cell disease (SCD) complications; however, drug labels currently advise discontinuation of breastfeeding during hydroxyurea therapy due to limited ...
Khaled Abduljalil +3 more
doaj +1 more source
ABSTRACT Transitioning from pediatric to adult care is a high‐risk period for individuals with sickle cell disease (SCD). An initial observation at one academic medical center suggested a sex‐based disparity in clinic populations, prompting a national investigation.
Laurie J. Duckworth +5 more
wiley +1 more source
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim +17 more
wiley +1 more source

